Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) rose 5.1% on Wednesday . The stock traded as high as $23.75 and last traded at $23.73, with a volume of 345,773 shares trading hands. The stock had previously closed at $22.57.

ENTA has been the subject of several research reports. Zacks Investment Research cut Enanta Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, April 12th. Vetr cut Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $35.45 target price for the company. in a research report on Monday, April 25th. Finally, JMP Securities cut Enanta Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, April 28th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $28.58.

The stock’s 50-day moving average price is $23.52 and its 200 day moving average price is $27.24. The company has a market capitalization of $449.85 million and a P/E ratio of 13.95.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Monday, May 9th. The company reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.10 by $0.19. The business earned $13 million during the quarter, compared to analysts’ expectations of $16.80 million. The firm’s revenue was down 77.4% on a year-over-year basis. During the same quarter last year, the business earned $1.49 earnings per share. Equities analysts anticipate that Enanta Pharmaceuticals Inc. will post $1.00 EPS for the current year.

Other hedge funds and institutional investors recently bought and sold shares of the company. Wells Fargo & Company MN raised its position in Enanta Pharmaceuticals by 142.4% in the fourth quarter. Wells Fargo & Company MN now owns 89,541 shares of the company’s stock valued at $2,956,000 after buying an additional 52,600 shares during the period. GSA Capital Partners LLP raised its position in Enanta Pharmaceuticals by 44.3% in the fourth quarter. GSA Capital Partners LLP now owns 80,322 shares of the company’s stock valued at $2,652,000 after buying an additional 24,670 shares during the period. Schroder Investment Management Group raised its position in Enanta Pharmaceuticals by 91.8% in the fourth quarter. Schroder Investment Management Group now owns 439,303 shares of the company’s stock valued at $14,506,000 after buying an additional 210,303 shares during the period. Tieton Capital Management LLC raised its position in Enanta Pharmaceuticals by 2.3% in the fourth quarter. Tieton Capital Management LLC now owns 93,863 shares of the company’s stock valued at $3,099,000 after buying an additional 2,130 shares during the period. Finally, First Trust Advisors LP bought a new position in Enanta Pharmaceuticals during the fourth quarter valued at $1,374,000.

Enanta Pharmaceuticals Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.